

1. Giussani M, Landoni E, Merlino G, Turdo F, Veneroni S, Paolini B, Cappelletti V, Miceli R, Orlandi R, Triulzi T, Tagliabue E. Extracellular matrix proteins as diagnostic markers of breast carcinoma. *J.Cell Physiol.* 2018.
2. Di Modica M, Regondi V, Sandri M, Iorio MV, Zanetti A, Tagliabue E, Casalini P, Triulzi T. Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers. *Cancer Lett.*, 384, 94-100, 2017.
3. Triulzi T, De Cecco L, Sandri M, Prat A, Giussani M, Paolini B, Carcangiu ML, Canevari S, Bottini A, Balsari A, Ménard S, Generali D, Campiglio M, Di Cosimo S, Tagliabue E. Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration. *Oncotarget*, 6, 28173-28182, 2015.
4. Castagnoli L, Iezzi M, Ghedini GC, Ciravolo V, Marzano G, Lamolinara A, Zappasodi R, Gasparini P, Campiglio M, Amici A, Chiodoni C, Palladini A, Lollini P, Triulzi T, Ménard S, Nanni P, Tagliabue E, Pupa SM. Activated d16HER2 homodimers and Src kinase mediate optimal efficacy for trastuzumab. *Cancer Res.*, 74, 6248-6259, 2014.
5. Triulzi T, Casalini P, Sandri M, Ratti F, Carcangiu ML, Colombo MP, Balsari A, Ménard S, Orlandi R, Tagliabue E. Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress. *PLoS ONE*, 8, e56761, 2013.
6. Magnifico A, Albano L, Campaner S, Delia D, Castiglioni F, Gasparini P, Sozzi G, Fontanella E, Ménard S, Tagliabue E. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to Trastuzumab. *Clin.Cancer Res.*, 15, 2010-2021, 2009.
7. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Ménard S, Tagliabue E, Balsari A. FOXP3 expression and overall patient survival in breast cancer. *J.Clin.Oncol.*, 27, 1746-1752, 2009.
8. Bergamaschi A, Tagliabue E, Sorlie T, Naume B, Triulzi T, Orlandi R, Tammi R, Giercksky H, Nesland JM, Ménard S, Borresen-Dale AL. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. *J.Pathol.*, 214, 357-367, 2008.
9. Gennari R, Ménard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, Oliviero B, Ballardini B, Da Prada G, Zambelli A, Costa A. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. *Clin.Cancer Res.*, 10, 5650-5655, 2004.
10. Tagliabue E, Agresti R, Carcangiu ML, Ghirelli C, Morelli D, Campiglio M, Martel M, Giovanazzi R, Greco M, Balsari A, Ménard, S. Role of HER2 in wound-induced breast carcinoma proliferation. *Lancet*, 362, 527-533, 2003.